Antioxidant Therapy Bypasses Genetic Defect in 22q11.2 Deletion Syndrome via Alternative Gene Networks

Scientists at the Fralin Biomedical Research Institute at VTC (search)Search term have demonstrated that an antioxidant therapy can bypass the neurodevelopmental deficits caused by 22q11.2 deletion syndrome (search)Search disease without correcting the underlying genetic mutation itself. The findings, published in Disease Models & Mechanisms, reveal a novel mechanistic strategy: activating compensatory gene networks rather than restoring baseline expression of deleted genes.

The research focused on 22q11.2 deletion syndrome (search)Search disease, the second most common genetic deletion disorder and among the strongest known genetic risk factors for schizophrenia (search)Search disease in humans. The syndrome affects approximately one in every 2,000 to 4,000 births and is also associated with autism spectrum disorder (search)Search disease and a range of cognitive and developmental challenges.

Mitochondrial Oxidative Stress as a Disease Driver

Using a mouse model of 22q11.2 deletion syndrome (search)Search disease — the LgDel mouse model — the researchers identified oxidative stress, a buildup of harmful oxygen-containing molecules inside brain cells, as a key contributor to abnormal brain development. Specifically, elevated reactive oxygen species and mitochondrial dysfunction were found to drive impaired dendritic branching and circuit formation in the affected neurons.

The team focused on upper layer cortical projection neurons (Layer 2/3 PNs), which are critical for mediating communication within the brain's neural networks. In the deletion model, these neurons exhibited disrupted growth and connectivity patterns.

NAC Treatment and Compensatory Gene Activation

The researchers treated mice with N-acetyl cysteineView drug details (NAC), a blood-brain barrier-permeable antioxidant, to determine whether reducing oxidative stress could restore healthy growth and connectivity. The treatment improved mitochondrial health, strengthened connections between neurons, and restored the growth of dendrites — the branch-like extensions on neurons that receive synaptic signals from other neurons.

Critically, the therapy did not restore the activity of genes disrupted by the deletion. Instead, it activated a different network of genes that enabled neurons to achieve many of the same developmental results.

"Think of it as a detour around a network of winding roads where several trees have fallen," said Anthony-Samuel LaMantia, professor at the Fralin Biomedical Research Institute at VTC (search)Search term and the study's corresponding author. "The detour still gets you to your destination even though the original route remains blocked. In this case, the therapy activates a different set of genes that helps neurons form functional brain circuits despite the genetic deletion."

Transcriptomic Insights

The study characterized both in vitro and in vivo responses to NAC. According to the published abstract, NAC ameliorated Layer 2/3 PN developmental pathology without restoring wild-type growth patterns or expression levels of downstream targets of 22q11-deleted genes. Instead, novel neuronal growth and antioxidant defense genes were differentially expressed compared to both the deletion model and wild-type controls — some generally NAC-regulated, others responsive only in the context of 22q11 deletion.

Notably, the Layer 2/3 PN-selective in vivo changes differed substantially from those observed in primary culture, underscoring the importance of assessing therapeutic responses within the intact cortical environment.

"That was surprising because the assumption behind most therapies is that you have to restore gene expression to its normal ground state," said LaMantia, who serves as director of the institute's Center for Neurobiology Research. "Our findings suggest that may not always be possible or even necessary. There can be therapeutic benefits from taking an alternate route."

Behavioral Improvements

Rather than replacing lost neurons, the treatment strengthened the connections among the neurons that remained, restoring the cumulative strength of communication signals within brain circuits that underlie learning and cognitive flexibility. In the mouse model, these improvements were accompanied by better performance on behavioral tasks that depend on those circuits.

A Paradigm Shift for Genetic Brain Disorders

Although additional research will be needed before the findings can be translated into human therapies, the study points to a new way of thinking about treatments for genetic brain disorders. Rather than trying to correct every disrupted gene or molecular pathway, researchers may be able to harness the natural ability of gene networks to help brain cells develop more normally.

"Gene networks are remarkably flexible," LaMantia added. "We may be able to develop therapies that engage that flexibility instead of trying to correct a specific genetic or molecular disruption that may be too difficult to manipulate directly."

The study was led by LaMantia with colleagues Shah Rukh, Daniel Meechan, Abra Roberts, Connor Siggins, Zachary Erwin, and Thomas Maynard of the Fralin Biomedical Research Institute. The research was supported by the National Institute of Mental Health, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the Red Gates Foundation.